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It has been known for many years that protective immunity against group A 
streptococcal infections is directed against the surface M protein of these orga- 
nisms.  Purified  M  proteins  are immunogenic  and  evoke opsonic antibodies  in 
laboratory animals  and  humans  (1-7).  In  addition  to  type-specific, protective 
immunity, M proteins from several serotypes of streptococci also elicit antibodies 
that crossreact with human  tissues, particularly  the myocardium (7-10).  These 
findings are of considerable  concern  to investigators attempting  to develop M 
protein  vaccines  that  would  protect  against  infection  by  strains  of group  A 
streptococci that  may give rise  to acute  rheumatic  fever and  rheumatic  heart 
disease. The fear has been that the vaccines themselves may evoke autoimmune 
responses that could lead to host tissue injury. 
To avoid the potential  immunological toxicity of intact  M proteins,  and also 
to  minimize  the  total  amount  of protein  included  in  streptococcal  vaccines, 
studies  have  been  undertaken  to determine  the protective immunogenicity  of 
natural and synthetic peptides of several serotypes of M protein (11-16). Peptides 
as small as  35  amino acid residues obtained by cyanogen bromide cleavage of 
type 24 M protein evoked opsonic antibodies in laboratory animals (11). Chem- 
ically synthesized peptides representing regions of types 5, 6, and 24 M proteins, 
ranging  in size from  10 to 35 amino acids, have proven to be effective immu- 
nogens (12-16). None of the peptides representing very limited regions of intact 
M  molecules  has  evoked  tissue-crossreactive  antibodies.  These  studies  have 
provided definitive evidence that the entire M protein molecule is not necessary 
to elicit protective immunity,  and that  type-specific epitopes may be separated 
from tissue-crossreactive regions of M protein. 
The present study was undertaken  to determine the precise location of pro- 
tective epitopes within the amino terminus of type 5 M protein, a rheumatogenic 
serotype with worldwide distribution.  We report here that a chemically synthe- 
sized  peptide  representing  the  first  35  amino  terminal  residues  of type  5  M 
protein was immunogenic in rabbits and evoked opsonic antibodies against type 
5  streptococci  that  did  not  crossreact  with  myocardial  tissue.  Using  a  set  of 
overlapping synthetic subpeptides, a  major protective region was localized to a 
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13-residue peptide within the 35-residue peptide. We believe these studies have 
relevance to the development of a safe and effective streptococcal vaccine. 
Materials and Methods 
Extraction and Purification of M Protein.  M proteins were purified from limited peptic 
digests of types 5, 6, 19, and 24 group A streptococci (2-4). The purified M proteins (pep 
M) were judged to be homogeneous by SDS-PAGE (3). 
Chemical Synthesis of  Peptides.  Overlapping polypeptides identical to the amino-terminal 
amino acid sequence of pep M5 (17) were synthesized by an automated peptide synthesizer 
(Beckman Instruments, Fullerton, CA) by a  solid-phase  method (18) as previously de- 
scribed (14). The peptides were purified by HPLC and sequenced by automated Edman 
degradation (13-15). The peptides synthesized for this study are designated SM5(1-35), 
SM5(14-35),  SM5(21-35),  SM5(26-35), and SM5(14-26).  An additional peptide represent- 
ing amino acid residues 14-26 was synthesized with a carboxyl-terminal cysteine, SM 5(14- 
26)C,  which allowed coupling to a  carrier  molecule using a  bifunctional crosslinking 
reagent. 
Conjugation of Synthetic Peptides.  SM5(1-35),  SM5(26-35),  and SM5(14-26)  were con- 
jugated to lysylated tetanus toxoid as previously described (15). SMS(14-26)C was conju- 
gated  to  KLH  using  succinimidyl-4-(N-maleimido-methyl)cyclohexane-l-carboxylate 
(SMCC) (Pierce Chemical Co., Rockford, IL) as described (19), with the modifications of 
Rothbard et al. (20). 
Immunization  of Rabbits.  New  Zealand White rabbits were  injected subcutaneously 
with  100  #g of the conjugated peptides, which had been emulsified in CFA (13-15). 
Blood was obtained before the initial injection, and at 2-wk intervals thereafter. At 4 and 
10 wk, the animals were given booster injections of 100 #g of the conjugated peptide in 
(0.02  M phosphate,  0.15  M  NaCI,  pH  7.4).  Rabbit antiserum against the natural M5 
protein was similarly prepared by immunizing with 100 t~g doses of pep M5 or against 
whole type 5 streptococci by injecting 10  ° streptococci (heat-killed, 56°C for 30 rain) 
intracutaneously in 1 mi PBS. Booster injections of the same dose were given every 4 wk 
for 12 wk; one-tenth of the dose was given intraperitoneally, followed several hours later 
by intravenous injection of the remainder of the organisms. 
M Protein Antibody Assays.  Sera were tested for the presence of the M protein antibodies 
by an ELISA using unconjugated synthetic peptides or pep  M proteins as solid-phase 
antigens, as previously described (7-21).  In some cases, ELISAs were performed using 
type 5 streptococci as particle-phase test antigens (22). ELISA inhibition experiments were 
performed by incubating a constant dilution of antiserum with increasing concentrations 
of synthetic peptides or pep M5, as soluble inhibitors (15-2 I). Opsonic antibodies were 
detected by in vitro opsonophagocytic assays (3), and the peptide specificity of opsonic 
antibodies directed against type 5 streptococci was determined by opsonization inhibition 
tests using the synthetic peptides as soluble inhibitors (7,  13). 
Affinity Purification of SM5(1-35) Antibodies  from Antiserum against Whole Type 5 Strepto- 
cocci.  Antibodies raised against whole type 5 streptococci that reacted with SM5(1-35) 
were  affinity purified  over  a  column  of CH-Sepharose  (Pharmacia  Fine  Chemicals, 
Uppsala, Sweden) to which SM5(1-35)  had been covalently linked (7,  9). The purified 
antibodies were dialyzed against PBS and concentrated to the original volume of serum 
by membrane filtration (YM 30 membrane; Amicon Corp., Danvers, MA). 
Detection of Heart-crossreactive Antibodies.  Indirect immunofluorescence tests for heart- 
crossreactive antibodies were performed using purified sarcolemmal membranes or thin 
sections of human heart tissue, as described elsewhere (7). Antibodies crossreactive with 
myosin were detected by ELISA (10). 
Results 
Amino Acid Sequences of  Chemically Synthesized Peptides.  The primary structures 
of the  overlapping  peptides  synthesized  for  this  study  were  determined  by DALE AND  BEACHEY 
TABLE  I 
Chemically Synthesized Peptides Corresponding to the Amino Terminus of Pep M5 
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Synthetic  Primary structure 
peptide 
SM5(1-35) 
SM5(14-35) 
SM5(21-35) 
SM5(26-35) 
SM5(14-26) 
SM5(14-26)C 
5  10  15  20  25  30  35 
AVTKGTINDPQAAKEALDKYELENHDLKTNNEGLK 
KEALDKYELENHDLKTNNEGLK 
ELENHDLKTNNEGLK 
DLKTNNEGLK 
KEALDKYELENHD 
KEALDKYELENHDC 
TABLE II 
Type-specific, Opsonic Antibodies Evoked in Rabbits Immunized 
with SM5(V35) 
Antiserum 
ELISA titer against:  Percent opsoni- 
zation of type 5 
SM5(1-35)  Pep M5  streptococci 
8425 
8425 
8426 
8426 
8427 
8427 
8513 
8513 
8514 
8514 
8515 
8515 
)relmmune 
12-wk 
prelmmune 
12-wk 
prelmmune 
12-wk 
)relmmune 
14-wk 
)relmmune 
14-wk 
pretmmune 
14-wk 
<200  <200  4 
25,600  3,200  86 
<200  <200  2 
51,200  12,800  86 
<200  <200  6 
51,200  6,400  96 
<200  <200  8 
25,600  3,200  86 
<200  <200  8 
25,600  6,400  84 
<200  <200  10 
25,600  6,400  66 
automated Edman degradation  to assure their identity with the native pep M5 
molecule  (Table  I).  All  of the  peptides  were  identical  to  the  corresponding 
regions of the primary structure of pep M5 (17). 
Immunogenicity  of SM5(1-35) and SM5(26-35).  Initial  experiments were per- 
formed to determine the immunogenicity of SM5(1-35), the longest polypeptide 
synthesized  for the  study,  and  SM5(26-35),  the  shortest  polypeptide,  both  of 
which had been covalently linked to tetanus toxoid. All six rabbits immunized 
with SM5(1-35) developed significant levels of antibody against the immunogen 
and  native  pep  M5,  as  determined  by  ELISA  (Table  II).  All  six  rabbits  also 
developed significant levels of opsonic antibodies against type 5 streptococci, as 
determined by in vitro opsonophagocytic tests (Table II). None of the immune 
sera crossreacted with human heart tissue or myosin, as determined by indirect 
immunofluorescence  tests  and  ELISA,  respectively.  These  results  show  that 1194  PROTECTIVE  M  PROTEIN  EPITOPES 
TABLE  III 
Type-specific, Nonopsonie Antibodies Evoked in Rabbits Immunized 
with SM5(26-35) 
Antiserum 
ELISA titer against: 
Percent phagocy- 
Type 5  tosis of type 5 
SM5(1-35)  Pep M5  strepto-  streptococci 
cocci 
8437  preimmune  <200  <200  <200  0 
8437  8-wk  51,200  12,800  <200  0 
8438 preimmune  <200  <200  <200  0 
8438 8-wk  6,400  6,400  <200  4 
8439 preimmune  <200  <200  <200  0 
8439 8-wk  12,800  3,200  <200  4 
SM5(1-35)  is  immunogenic and  evokes  antibodies  that  recognize  protective 
epitopes of type 5 M protein on the surface of the streptococcus. 
Three  rabbits  were  also  immunized  with  SM5(26-35).  The  immune  sera 
contained significant levels of antibody against SM5(1-35) and pep M5 (Table 
III).  In  contrast  to  the  SM5(1-35)  immune sera,  SM5(26-35)  failed to  evoke 
opsonic antibodies against type 5 streptococci, although the ELISA titers against 
pep M5 were equivalent for both sets of antisera. These results suggested that 
the antibodies raised against SM5(26-35)  were binding to epitopes of pep  M5 
that  may not  be  exposed on  the surface of type  5  streptococci.  To  test  this 
hypothesis, a particle-phase ELISA was performed using whole type 5 strepto- 
cocci as the test antigen. None of the SM5(26-35) immune sera reacted with type 
5 streptococci (Table III), confirming that the antibodies were directed against 
pep M5 epitopes that were not exposed on the type 5  M protein in its native 
conformation on the surface of the organism. 
Peptide Specificity of Pep M5-reactive Antibodies  Evoked by SM5(I-35).  To deter- 
mine  the  location  of epitopes  within  SM5(1-35)  that  evoked antibodies  that 
reacted with native pep M5, ELISA inhibition tests were performed using the 
overlapping synthetic peptides as soluble inhibitors of SM5(1-35) antibody bind- 
ing to pep M5 (Fig.  1). As expected, increasing concentrations of SM5(1-35), the 
immunizing antigen, and pep M5, the solid-phase test antigen, completely inhib- 
ited  the  binding  of SM5(1-35)  antibodies  to  pep  M5  (Fig.  1).  Interestingly, 
SM5(14-35)  also  completely inhibited  the  binding  of antibodies  to  pep  M5, 
suggesting that all of the relevant epitopes of SM5(1-35), or those that evoke pep 
M5-reactive antibodies, reside in the SM5(14-35) peptide. SM5(21-35) partially 
inhibited antibody binding, whereas SM5(26-35) had no effect (Fig. 1). Although 
these  data  were obtained  using  antiserum from  one  rabbit  immunized with 
SM5(1-35), similar patterns of inhibition were obtained from all six immune sera 
(data not shown). 
Taken together, the data outlined thus far suggest that all of the immunogenic 
protective epitopes of SM5(1-35) reside between amino acid residues 14 to 26: 
(a) all of the pep M5 antibodies evoked by SM5(1-35) were inhibited by SM5(14- DALE  AND  BEACHEY  1195 
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FIGURE  1.  Peptide specificity of pep M5-reactive antibodies raised  against  SM5(1-35) as 
determined by inhibition of ELISA. A constant dilution of anti-SM5(]-35) was incubated with 
increasing concentrations o£ pep M5 (11), SM5(]-35) (O), SM5(] 4-35) (A), SM5(21-35) (A), or 
SM5(26-35) (O) used as soluble inhibitors of antibody binding to the natural pep M5 antigen, 
which was immobilized on plastic plates. The highest concentration of the synthetic peptides 
was 40 nM, while the highest concentration of pep M5 was 10/Lg/ml. 
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FIGURE 2.  ELISA inhibition by the subpeptide SM5(14-26) of pep M5-reactive antibodies 
raised against SM5(1-35). A constant dilution of anti-SM5(l-35) was incubated with increasing 
concentrations of either  pep  M5  (e)  or  SM5(14-26)  (O)  as soluble  inhibitors of antibody 
binding to pep M5, which was the solid-phase antigen. The highest concentration of SM5(I 4- 
26) was 40 nM, and the highest concentration of pep M5 was  10 ug]ml. 
35); (b) none of the pep M5  reactive antibodies was inhibited by SM5(26-35); 
and (c) SM5(26-35) evoked antibodies that were nonopsonic. ELISA inhibition 
experiments with SM 5(1-35) as the solid-phase antigen and pep M5 as the soluble 
inhibitor  revealed  that  not all  of the antibodies were  inhibited by pep  M5, 
indicating that a portion of the antibodies were peptide specific (data not shown). 
Antigenicity of  SM5(14-26).  To test the hypothesis that the protective epitopes 
of SM5(1-35) were located between amino acid residues 14 and 26, this peptide 
was synthesized and  tested for  its  ability  to  inhibit type-specific and opsonic 
antibodies evoked by SM5(1-35). Increasing concentrations of SM5(14-26) com- 
pletely  inhibited  SM5(1-35)  antibody  binding to  pep  M5,  as  determined by 
ELISA inhibition studies (Fig. 2). 
Opsonization-inhibition assays were also performed to test for the presence of 
protective epitopes within SM5(14-26). Opsonic antibodies against type 5 strep- 
tococci that were evoked by SM5(1-35) were completely inhibited by SM5(14- 
26) (Table IV). Total inhibition was also observed with SM5(1-35),  the immu- 
nogen, and pep MS,  the natural peptide (Table  IV).  Opsonization of type 5 
streptococci by  the  remaining SM5(1-35)  antisera  was  similarly inhibited by 1196  PROTECTIVE  M  PROTEIN  EPITOPES 
TABLE  IV 
Opsonization Inhibition of SMS(1-35) Antisera with SM5(14-26) 
Percent opsonization  Test serum  Inhibitor  of type 5 streptococci 
8426 preimmune 
8426  10-wk 
None  0 
None  42 
SM5(1-35)  2 
SM5(14-26)  0 
SM5(1-20)  0 
SM5(20-40)  48 
Pep M5  4 
8427 preimmune 
8427  10-wk 
None  10 
None  44 
SM5(1-35)  2 
SM5(14-26)  2 
SM5(1-20)  22 
SM5(20-40)  8 
Pep M5  8 
SM5(14-26),  indicating that the immunodominance of this region of the poly- 
peptide was not the result of individual variation in immune responses. 
Because  our  previous  studies have  shown  that  SM5(1-20)  evoked opsonic 
antibodies against type 5 streptococci whereas SM5(20-40) did not (15), we also 
used these two peptides as inhibitors of opsonic antibodies raised against SM5(1- 
35) (Table IV). Opsonization of type 5 streptococci by one of the antisera (8426) 
was totally inhibited by SM5(1-20),  but not at all  by SM5(20-40)  (Table  IV). 
Taken  together  with  the  finding that  SM5(14-26)  also  completely inhibited 
opsonization by this antiserum, the data suggest that all of the opsonic antibodies 
are directed against the region between amino acid residues 14 and 20. Inhibition 
studies using another antiserum showed that opsonization of type 5 streptococci 
was partially inhibited by SM5(1-20) and alniost totally inhibited by SM5(20-40), 
indicating that the opsonic antibodies in this antiserum were directed against 
epitopes located in the 14-20 and the 20-26 regions of the SM5(1-35) peptide. 
The data  presented thus far  indicate that  all  of the antibodies evoked by 
SM5(1-35)  that  reacted  with pep  M5  and  type  5  streptococci were  actually 
directed against the region represented by SM5(14-26). We wished to determine 
whether this region of type 5 M protein was also immunodominant and evoked 
protective antibodies in animals immunized with whole type 5  streptococci, a 
situation  that  more  closely  resembles  the  immune response  during  natural 
infection. Antiserum against intact type 5 organisms was affinity purified over a 
Sepharose-SM5(1-35) column, and the purified antibodies were used in opsoni- 
zation-inhibition assays (Table V). The SM5(1-35)-reactive antibodies opsonized 
type 5  streptococci, and the opsonization was completely inhibited by SM5(1- 
35), pep MS, and SM5(14-26). These data indicate that the immune response to 
the amino terminus of type 5 M protein on the surface of the organism is similar 
to the immune response against SM5(1-35).  Although opsonization of type 5 
streptococci  by  the  affinity-purified antibodies  was  completely inhibited  by 
SM5(14-26),  control experiments using unfractionated antiserum clearly indi- DALE AND  BEACHEY 
TABLE V 
Peptide Specificity of Opsonic Antibodies Evoked by Intact 
Type 5 Streptococci 
Percent opsonization 
Antiserum  Inhibitor  of type 5 streptococci 
7903 [affinity-purified  over  None  52 
SM5(1-35)1  SM5(1-35)  10 
SM5(14-26)  10 
Pep M5  6 
7903 (unfractionated)  None  88 
SM5(1-35)  88 
SM5(14-26)  86 
Pep M5  10 
TABLE  VI 
Type-specific, Opsonic Antibodies Evoked in Rabbits Immunized with SM5(14-26)C 
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Antiserum 
ELISA titer against:  Percent phagocy- 
tosis of type 5 
SM5(1-35)  SM5(14-26)  Pep M5  streptococci 
8516 preimmune  <200  <200  <200  8 
8516 14-wk  6,400  25,600  12,800  64 
8517 preimmune  <200  <200  <200  8 
8517 14-wk  25,600  25,600  25,600  46 
8518 preimmune  <200  <200  <200  8 
8518 14-wk  12,800  25,600  12,800  76 
cated the presence of additional opsonic epitopes that were not represented in 
SM5(1-35) but that were present in pep M5 (Table V). 
Immunogenicity of SM5(14-26).  To determine the immunogenicity  of SM5(14- 
26), rabbits were immunized with the synthetic peptide that had been covalently 
linked to tetanus toxoid. SM5(14-26)  in the conjugated form proved to be an 
ineffective immunogen, possibly because  the  carrier  molecule was  covalently 
linked  in  such  a  way that  it  masked  or  altered  the  M  protein  epitopes.  We 
therefore synthesized an additional peptide SM5(14-26)C, which was crosslinked 
to  KLH via the carboxyl-terminal cysteine residue (19,  20).  All three rabbits 
immunized with this conjugate developed significant levels of antibodies against 
SM5(14-26),  SM5(1-35),  and  pep  M5,  as  measured by  ELISA, and all  three 
opsonized type 5 streptococci, as determined by in vitro opsonization tests (Table 
VI). 
The protective immunogenicity  of  SM 5(14-26)C and S M5(I-3 5) was confirmed 
in indirect bactericidal tests (Table  VII).  Type 5  streptococci were rotated in 
whole human blood, to which was added either preimmune or immune serum. 
The immune sera against both synthetic peptides contained bactericidal antibod- 
ies, as indicated by a significant reduction in CFU after a 3-h rotation in the test 
mixture (Table VII). 
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TABLE VII 
Bactericidal Antibodies Against Type 5 Streptococci Evoked in Rabbits 
by SM5(1-35) and SM5(14-26) 
Antiserum  Immunizing antigen 
Number of colonies of 
type 5 streptococci sur- 
viving after 3 h growth 
in test mixture (inocu- 
lure of 6 CFU) 
8518 preimmune  SM5(14-26)C  >2,000 
8518 14-wk  210 
8514 preimmune  SM5(1-35)  :>2,000 
8514 14-wk  94 
8329 preimmune  Pep M5  >2,000 
8329 14-wk  0 
TABLE  VIII 
Type-specific and Crossreactive Antibodies Evoked in Rabbits Immunized with 
SM5(1-35) or SM5(14-26) 
Antiserum  Immunizing 
antigen 
ELISA titer against: 
Pep M5  Pep M6  Pep M19  Pep M24 
8513  SM5(1-35)  3,200  200  1,600  <200 
8514  6,400  400  1,600  <200 
8515  6,400  400  3,200  <200 
Preimmunepool  <200  <200  <200  <200 
8516  SM(14-26)C  25,600  200  800  <200 
8517  51,200  200  400  <200 
8518  51,200  400  200  <200 
Preimmune pool  <200  <200  <200  <200 
Protein.  Because previous studies (7-10, 23) have shown that pep M5 contains 
not  only  type-specific  but  also  crossreactive  epitopes,  we  wished  to  test  the 
immune sera raised against the synthetic peptides for the presence of antibodies 
directed against heterologous M proteins (Table VIII). SM5(1-35) evoked signifi- 
cant levels of crossreactive antibodies against pep M 19,  very low levels against 
pep M6, and none against pep M24, as measured by ELISA. The SM5(14-26)C 
immune sera did not crossreact significantly with any of the heterologous antigens 
tested. Although SM5(1-35) appeared to contain epitopes that were shared with 
pep M 19,  none of the antisera opsonized type  19 streptococci, suggesting  that 
the  crossreactive antibodies  may have  been  directed against  nonprotective  M 
protein epitopes on the surface of the organisms. 
Discussion 
The  ability to identify limited  regions  of M  protein  molecules  that  contain 
protective epitopes,  as  opposed  to  tissue-crossreactive  and  nonprotective  epi- 
topes,  may  be  an  important  step  in  developing  safe  and  effective  group  A DALE  AND  BEACHEY  1199 
streptococcal vaccines. We have recently shown that pepsin extracted M protein 
fragments from types 5, 6, and 19 streptococci contain epitopes that crossreact 
with sarcolemmal membrane proteins of human myocardium (7-9) and myosin 
(10), thus making the pep M proteins unsuitable for vaccine preparation. Previous 
studies (11-16) have been designed to determine the minimum peptide structures 
of several  M  proteins  that  retain  protective  immunogenicity and  not  tissue 
crossreactivity. Chemically synthesized peptides of type 24 M protein, ranging in 
size from 13 to 35 amino acid residues, were found (12, 14) to evoke protective 
antibody  responses  in  laboratory  animals.  Most recently,  synthetic  peptides 
representing the amino terminus of type 6  M protein were also shown (16) to 
produce protective, and not heart-crossreactive, immunity. Similar studies (15) 
have been performed with synthetic peptides of type 5 M protein which showed 
that SM5(1-20)  evoked protective antibodies, whereas SM5(20-40)  did not. 
The present study was undertaken to identify precisely the primary structure 
of the amino terminus of type 5  M protein that contains protective antigenic 
determinants. We first showed that SM5(1-35)  was immunogenic and evoked 
opsonic antibodies in rabbits.  Using overlapping peptides, we identified three 
immunologically distinct regions of SM5(1-35):  the amino terminus, which did 
not  evoke  M5-reactive antibodies;  the  carboxy  terminus,  which evoked  M5 
antibodies that were nonopsonic; and the region between residues 14 and 26, 
which contained the immunodominant protective epitopes of SM 5( 1-35). Further 
studies using SM5(1-20) and SM5(20-40) showed that all of the opsonic antibodies 
in one SM5(1-35) antiserum were completely inhibited by SM5(1-20),  suggesting 
that at least one protective epitope resides between residues 14 and 20. Opsoni- 
zation of type  5  streptococci by another antiserum was partially inhibited by 
SM5(1-20),  and almost totally inhibited by SM5(20-40), indicating that another 
protective epitope is located between residues 20 and 26. Our previous finding 
(15) that SM5(20-40) did not evoke opsonic antibodies, yet in the present study 
was capable of inhibiting opsonization by antibodies raised against SM5(1-35) 
most likely reflects differences between immunogenicity and antigenicity of the 
synthetic peptides. SM5(I 4-26)C, when linked to an appropriate carrier molecule, 
evoked opsonic antibodies against type 5 streptococci. Thus, by using a set of 
overlapping synthetic peptides representing type 5 M protein, we have identified 
a discrete region of the molecule, composed of only 13 amino acids, that retains 
protective immunogenicity and does not evoke host tissue-crossreactive antibod- 
ies. 
The three immunologically different regions of SM5(1-35)  were detected by 
methods designed to determine the functional activity of antipeptide antibodies. 
The titers of SM5(1-35) antisera against the synthetic peptide were consistently 
higher than those against pep M5, the natural protein, suggesting that at least 
some of the antibodies  were peptide-specific. This  was confirmed by ELISA 
inhibition experiments, which showed that not all of the SM5(1-35)  antibodies 
were inhibited by pep M5.  The finding that opsonic antibodies raised against 
whole  type  5  streptococci  that  were  affinity  purified  with  SM5(1-35)  were 
completely inhibited  by  SM5(14-26)  confirms the  immunodominance of this 
region of the amino terminus, and suggests that our findings were not artifacts 
of the synthetic immunogen or the coupling procedure. 1200  PROTECTIVE  M  PROTEIN  EPITOPES 
Recent evidence (24) suggests that the ability of antibodies evoked by synthetic 
peptides to recognize epitopes within the natural protein is partly a  function of 
the atomic mobility of the structure of its native state. Although such data are 
not yet available for M protein molecules, Manjula and Fischetti, and Phillips et 
al. (25-27) have previously shown that a consistent structural feature among the 
M proteins sequenced thus far is a seven-residue periodicity with respect to polar 
and noncharged amino acids, which led them to predict an a-helical secondary 
structure.  The  a-helical  potential  of pep  M5  begins at residues  14-17  and  is 
particularly  high between residues 27 and 54 (25,  28).  Herein,  we found that 
the  opsonic  epitopes  of  SM5(1-35)  corresponded  to  the  region  in  pep  M5 
(residues  14-26)  that displays only moderate a-helical  potential (25,  28),  sug- 
gesting that this secondary structural configuration may be related to immuno- 
dominance and the ability of antipeptide antibodies to react  with the natural 
protein. We do not mean to imply that the region of SM5(1-35) encompassed by 
residues 14-26 contains the only opsonic epitopes of the amino terminus of type 
5 M protein, but rather that it is immunodominant when animals are immunized 
with SM5(1-35).  For example, in this study the amino-terminal  13 amino acid 
residues of SM5(1-35)  did not evoke opsonic antibodies, yet we have recently 
shown (E.  H.  Beachy, manuscript in preparation) that a  synthetic peptide copy 
of the first  10 amino acids of pep M5 evokes opsonic antibodies. This finding 
indicates  that  the  immunogenicity of a  particular  primary  structure  may  be 
enhanced when it is presented to the immune system in isolated form, which is 
consistent with data presented by other investigators (20). 
Although the correlations of peptide structure with immunological function 
are  highly  speculative,  we  believe  that  such an  approach  may be  valuable  in 
developing an  M  protein  vaccine.  Previous data  support  the concept that  the 
amino-terminal regions of M proteins evoke opsonic antibodies (15,  16).  Thus 
far, none of the synthetic peptides of these M proteins has produced crossreactive 
antibodies. An effective streptococcal vaccine most likely will need to be formu- 
lated from protective fragments of M proteins representing as many as  15-20 
rheumatogenic serotypes of streptococci. The ability to pr¢cisely identify protec- 
tive as opposed to nonprotective and heart-crossreactive M protein epitopes will 
allow the disposal of the majority of the molecule, therefore minimizing the total 
amount of protein injected and reducing the risk of potentially harmful autoim- 
mune reactions. We believe that studies of additional M proteins, using methods 
similar to those reported here, may reveal certain consistencies in the structures 
of various M proteins as they are related to immunological function. 
Summary 
We have used a set of overlapping chemically synthesized peptides representing 
the amino terminus of type 5 streptococcal M protein to localize protective, as 
opposed to nonprotective and tissue-crossreactive epitopes that might be appro- 
priate for vaccine formulations. Rabbit antisera raised against SM5(1-35) reacted 
in high titer with pep M5 by ELISA and opsonized type 5 streptococci. None of 
the antisera  crossreacted  with human heart  tissue or myosin. Antisera against 
SM5(26-35)  reacted with SM5(1-35) and pep M5 but failed to opsonize type 5 
streptococci.  Particle-phase ELISA indicated that SM5(26°35) antibodies were DALE  AND  BEACHEY  1201 
directed against nonprotective determinants of pep M5 that were not exposed 
on the surface of viable organisms. Opsonization and ELISA inhibition assays 
showed that, of the SM5(1-35) antibodies that reacted with M5, all were inhibited 
by SM5(14-35), whereas none was inhibited by SM5(26-35), suggesting that the 
protective epitopes of SM5(1-35) resided between residues 14 and 26. This was 
confirmed by subsequent chemical synthesis of this region; SM5(14-26)  totally 
inhibited SM5(1-35) antibodies that reacted with pep M5 in ELISA, and com- 
pletely inhibited opsonization of type 5  streptococci by SM5(1-35)  antibodies. 
SM5(14-26) evoked high titers of type-specific, opsonic antibodies against type 5 
streptococci, confirming the protective immunogenicity of this  13-residue pep- 
tide of type 5 M protein. 
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